01222nas a2200409   4500000000100000000000100001000000100002008004100003653001100044653005000055653001100105653000900116653001600125653005800141653001000199653003500209653005600244653002200300653004800322653000900370653004700379653004800426100002200474700001600496700001500512700001600527700001100543700001400554700001400568700001300582700001400595245013600609250001500745300001300760490000700773020003200780       2025                            d10aHumans10a*Aripiprazole/therapeutic use/adverse effects10aFemale10aMale10aMiddle Aged10a*Antipsychotic Agents/therapeutic use/adverse effects10aAdult10a*Mental Disorders/drug therapy10aQuetiapine Fumarate/therapeutic use/adverse effects10aTreatment Outcome10aRisperidone/therapeutic use/adverse effects10aAged10aOlanzapine/therapeutic use/adverse effects10aHospitalization/statistics & numerical data1 aA. Richards-Belle1 aN. Launders1 aS. Hardoon1 aA. Richards1 aK. Man1 aN. Davies1 aE. Bramon1 aJ. Hayes1 aD. Osborn00aComparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation  a2025/01/23  ae10045200 v22  a1549-1277 (Print)
1549-1277